$-0.15 EPS Expected for pSivida Corp. (PSDV); Dime Community Bancshares (DCOM) Shorts Lowered By 9.86%

January 18, 2018 - By Vivian Park

Dime Community Bancshares (NASDAQ:DCOM) had a decrease of 9.86% in short interest. DCOM’s SI was 1.12M shares in January as released by FINRA. Its down 9.86% from 1.24M shares previously. With 209,600 avg volume, 5 days are for Dime Community Bancshares (NASDAQ:DCOM)’s short sellers to cover DCOM’s short positions. The SI to Dime Community Bancshares’s float is 4%. The stock increased 0.23% or $0.05 during the last trading session, reaching $21.75. About 126,642 shares traded. Dime Community Bancshares, Inc. (NASDAQ:DCOM) has risen 10.21% since January 18, 2017 and is uptrending. It has underperformed by 6.49% the S&P500.

Analysts expect pSivida Corp. (NASDAQ:PSDV) to report $-0.15 EPS on February, 6.After having $-0.15 EPS previously, pSivida Corp.’s analysts see 0.00% EPS growth. The stock decreased 1.82% or $0.02 during the last trading session, reaching $1.08. About 277,079 shares traded. pSivida Corp. (NASDAQ:PSDV) has declined 20.28% since January 18, 2017 and is downtrending. It has underperformed by 36.98% the S&P500.

Dime Community Bancshares, Inc. operates as the unitary savings bank holding firm for Dime Community Bank that provides financial services and loans for housing in New York. The company has market cap of $813.95 million. It accepts deposit products, such as savings, money market, and interest bearing and non-interest bearing checking accounts, as well as certificates of deposit. It has a 21.88 P/E ratio. The firm also offers multifamily residential and commercial real estate loans; small investment property loans; one- to four-family residential and condominium/cooperative apartment loans; home equity and improvement loans; equity lines of credit on multifamily residential and commercial real estate loans; and commercial and industrial loans, including acquisition, land development and construction loans, finance loans and leases, and small business administration loans.

Investors sentiment decreased to 0.81 in 2017 Q3. Its down 0.56, from 1.37 in 2017Q2. It dived, as 11 investors sold Dime Community Bancshares, Inc. shares while 48 reduced holdings. 16 funds opened positions while 32 raised stakes. 24.42 million shares or 0.22% less from 24.47 million shares in 2017Q2 were reported. Raymond James & Assoc reported 0% in Dime Community Bancshares, Inc. (NASDAQ:DCOM). Moreover, Ulysses has 0.23% invested in Dime Community Bancshares, Inc. (NASDAQ:DCOM) for 100,000 shares. Polaris Capital Management Lc has invested 1.14% of its portfolio in Dime Community Bancshares, Inc. (NASDAQ:DCOM). Wells Fargo And Mn has 0% invested in Dime Community Bancshares, Inc. (NASDAQ:DCOM). Gemmer Asset Mngmt Limited Liability Company stated it has 0% in Dime Community Bancshares, Inc. (NASDAQ:DCOM). Pub Sector Pension Board holds 0% or 19,647 shares in its portfolio. Metropolitan Life Ins has 0% invested in Dime Community Bancshares, Inc. (NASDAQ:DCOM). 67,473 were reported by Rhumbline Advisers. Blackrock, a New York-based fund reported 4.16M shares. Icon Advisers Com holds 0.07% of its portfolio in Dime Community Bancshares, Inc. (NASDAQ:DCOM) for 43,600 shares. Us Fincl Bank De accumulated 206 shares. Fincl Bank Of Ny Mellon Corporation holds 475,599 shares or 0% of its portfolio. 69,530 were accumulated by First Advisors Limited Partnership. Neuberger Berman Group Inc Ltd Liability has invested 0% in Dime Community Bancshares, Inc. (NASDAQ:DCOM). Ny State Common Retirement Fund reported 0% of its portfolio in Dime Community Bancshares, Inc. (NASDAQ:DCOM).

Among 5 analysts covering Dime Community Bancshares (NASDAQ:DCOM), 1 have Buy rating, 1 Sell and 3 Hold. Therefore 20% are positive. Dime Community Bancshares had 18 analyst reports since July 29, 2015 according to SRatingsIntel. As per Friday, November 3, the company rating was downgraded by PiperJaffray. PiperJaffray upgraded Dime Community Bancshares, Inc. (NASDAQ:DCOM) on Tuesday, May 9 to “Overweight” rating. The company was maintained on Tuesday, January 2 by Barclays Capital. The rating was maintained by Keefe Bruyette & Woods on Tuesday, October 3 with “Hold”. On Wednesday, October 11 the stock rating was maintained by Barclays Capital with “Underweight”. Piper Jaffray maintained it with “Buy” rating and $22.5000 target in Thursday, July 27 report. The company was maintained on Thursday, December 21 by Keefe Bruyette & Woods. As per Thursday, October 26, the company rating was maintained by Piper Jaffray. The firm has “Neutral” rating given on Wednesday, September 16 by Piper Jaffray. Barclays Capital downgraded Dime Community Bancshares, Inc. (NASDAQ:DCOM) on Tuesday, December 6 to “Underweight” rating.

Among 6 analysts covering pSivida (NASDAQ:PSDV), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. pSivida had 17 analyst reports since October 15, 2015 according to SRatingsIntel. The company was maintained on Wednesday, October 11 by H.C. Wainwright. The firm has “Buy” rating given on Wednesday, September 27 by H.C. Wainwright. The rating was maintained by H.C. Wainwright on Friday, June 23 with “Buy”. The firm earned “Buy” rating on Wednesday, June 14 by H.C. Wainwright. Northland Capital maintained it with “Buy” rating and $1000 target in Wednesday, June 14 report. The rating was initiated by FBR Capital on Thursday, October 15 with “Outperform”. Ladenburg maintained it with “Buy” rating and $12.5000 target in Tuesday, June 13 report. The stock of pSivida Corp. (NASDAQ:PSDV) has “Buy” rating given on Wednesday, November 8 by H.C. Wainwright. The firm earned “Buy” rating on Tuesday, June 13 by FBR Capital. The firm has “Buy” rating given on Tuesday, January 9 by H.C. Wainwright.

pSivida Corp. develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the United States and the United Kingdom. The company has market cap of $48.88 million. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior segment uveitis. It currently has negative earnings. The firm is also developing Durasert, an injectable, sustained-release micro-insert, which is in Phase III clinical trials for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: